UK Clinicians Sound Alarm on Lack of Regulation in ADHD Care Amid Rising Costs
A recent surge in private clinics offering ADHD assessments and treatment has raised concerns among UK-trained consultant psychiatrists, who are warning that the lack of effective regulation is putting patients at risk. For Dr Vicky Cleak, an expert in adult ADHD assessment and treatment, the situation is "deeply troubling" as she faces a lengthy wait to register her practice with the Care Quality Commission (CQC) before being able to see patients.
The UK's National Health Service (NHS) has awarded contracts to multiple companies without CQC registration, leaving patients vulnerable to unqualified practitioners. Furthermore, some healthcare professionals, such as psychologists working alongside prescribing pharmacists, are not subject to the same level of regulation, making it easier for "diagnosis and treatment" services to pop up overnight.
Dr Cleak's experiences in the private sector have given her a unique insight into the consequences of this lack of regulation. She describes the model used by large providers as "contract-driven and narrowly focused," prioritizing throughput over patient need, with clinicians under pressure to replace one another frequently. This can lead to fragmented care and patients only discovering their clinician's departure after it has happened.
The NHS's own incentives for prescribing medication have also raised concerns. In Dr Cleak's experience, patients may be prescribed amphetamines as a "quick fix" before therapy is even considered. The long-term health costs of this approach are significant, with some individuals experiencing dependency and damage from these medications.
Another contributor, Mona Sood, warns parents about the risks of unregulated ADHD provision for their children. With only psychostimulants or amphetamines recommended by the NHS National Institute for Health and Care Excellence, non-pharmacological treatment options that prioritize neuroplasticity are often overlooked. As a result, patients may be left with long-term health costs without access to effective, non-invasive treatments.
The lack of regulation in ADHD care is a pressing concern, as patients rely on the NHS to provide high-quality assessments and treatment. Dr Cleak's experiences highlight the need for better oversight and prioritization of patient needs over profit-driven models.
A recent surge in private clinics offering ADHD assessments and treatment has raised concerns among UK-trained consultant psychiatrists, who are warning that the lack of effective regulation is putting patients at risk. For Dr Vicky Cleak, an expert in adult ADHD assessment and treatment, the situation is "deeply troubling" as she faces a lengthy wait to register her practice with the Care Quality Commission (CQC) before being able to see patients.
The UK's National Health Service (NHS) has awarded contracts to multiple companies without CQC registration, leaving patients vulnerable to unqualified practitioners. Furthermore, some healthcare professionals, such as psychologists working alongside prescribing pharmacists, are not subject to the same level of regulation, making it easier for "diagnosis and treatment" services to pop up overnight.
Dr Cleak's experiences in the private sector have given her a unique insight into the consequences of this lack of regulation. She describes the model used by large providers as "contract-driven and narrowly focused," prioritizing throughput over patient need, with clinicians under pressure to replace one another frequently. This can lead to fragmented care and patients only discovering their clinician's departure after it has happened.
The NHS's own incentives for prescribing medication have also raised concerns. In Dr Cleak's experience, patients may be prescribed amphetamines as a "quick fix" before therapy is even considered. The long-term health costs of this approach are significant, with some individuals experiencing dependency and damage from these medications.
Another contributor, Mona Sood, warns parents about the risks of unregulated ADHD provision for their children. With only psychostimulants or amphetamines recommended by the NHS National Institute for Health and Care Excellence, non-pharmacological treatment options that prioritize neuroplasticity are often overlooked. As a result, patients may be left with long-term health costs without access to effective, non-invasive treatments.
The lack of regulation in ADHD care is a pressing concern, as patients rely on the NHS to provide high-quality assessments and treatment. Dr Cleak's experiences highlight the need for better oversight and prioritization of patient needs over profit-driven models.